Roivant and Priovant won FDA approval for LISRAYA (brepocitinib) in dermatomyositis — 55% of patients achieved both symptom improvement and minimal steroid use at 52 weeks. But the label carries a full JAK boxed warning, which makes the steroid-sparing case the entire commercial argument. Also: Spyre Therapeutics' anti-TL1A antibody missed in rheumatoid arthritis, erasing more than $1 billion in market value; Amgen and AstraZeneca's Tezspire (tezepelumab) hit all endpoints in Phase 3 eosinophilic esophagitis, setting up a fight with Dupixent; CStone's CS2009 trispecific posted deep responses in first-line lung cancer; and Verrica and Corvus each advanced their programs.


Alex Mercer and Maya Patel host the Daily Roundup for August 27. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

Rss
Podden och tillhörande omslagsbild på den här sidan tillhör BZ Group. Innehållet i podden är skapat av BZ Group och inte av, eller tillsammans med, Poddtoppen.